Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection
November 22, 2017
November 22, 2017
TITUSVILLE, New Jersey, Nov. 22 -- Johnson and Johnson issued the following news release:
Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved JULUCA(R), the first, complete, single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain adults living with the disease who are virologically suppressed.
JULUCA(R) is a once-daily, . . .
Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved JULUCA(R), the first, complete, single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain adults living with the disease who are virologically suppressed.
JULUCA(R) is a once-daily, . . .